NDA
21-515
WELLBUTRIN
XL
5. References
1.
Hesse
LM, von Moltke LL, Shader RI, Greenblatt DJ.
Ritonavir, efavirenz, and nelfinavir inhibitor CYP2B6 activity in vitro:
Potential drug interactions with bupropion.
Drug Metab Dispos 2001; 29(2):100-102.
2.
Hess
LM, Venkatakrishnan K, Court M, von Moltke LL, Duan SX, Shader RI et al. Cyp2B6 Mediates the In Vitro Hydroxylation
of Bupropion: Potential Drug
Interactions With Other Antidepressants. Drug Metab Disp 2000; 28(10):1176.
3.
Bertelsen
KM, Venkatakrishnam K, von Moltke LL, Obach RS, Greenblatt DJ. Apparent mechanism-based inhibition of human
CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31(3):289-293.
4.
Belle
DJ, Ernest S, Sauer J-M, Smith BP, Thomasson HR, Witcher JW. Effect of potent CYP2D6 inhibition by
paroxetine on atomoxetine pharmacokinetics.
J Clin Pharmacol 2002; 42:1219-1227.
5.
Brockmoller
J, Kirchheiner J, Klein C, Sasse J, Roots I.
Variability of bupropion pharmacokinetics in relation to amino acid
polymorphism in CYP2B6. Clin Pharmacol
Ther 2003; 73(2):P56.
6.
Bjornsson
TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al. The conduct of in vitro and in vivo
drug-drug interaction studies: a Pharmaceutical research and Manufacturers of
America (phRMA) perspective. Drug Metab
Dispos 2003; 31 (7):815-832.
7.
Gerner
RH, Kaufman KR, Rosen R. Seizures
associated with bupropion and SSRIs and serum levels. Biol Psychiatry 1998; 43:101s.
12
Back a Page
Next Page
Back to Wellbutrin XL NDA Index Page
Back to Main Index Page